Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Adamas Pharmaceuticals stock

Learn how to easily invest in Adamas Pharmaceuticals stock.

Adamas Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Adamas Pharmaceuticals shares (ADMS) are listed on the NASDAQ and all prices are listed in US Dollars. Adamas Pharmaceuticals employs 138 staff and has a trailing 12-month revenue of around $88.2 million.

How to buy shares in Adamas Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADMS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Adamas Pharmaceuticals stock price (NASDAQ: ADMS)

Use our graph to track the performance of ADMS stocks over time.

Adamas Pharmaceuticals shares at a glance

Information last updated 2022-01-23.
52-week range$4.48 - $8.25
50-day moving average $7.00
200-day moving average $5.54
Wall St. target price$8.52
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.62

Buy Adamas Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Adamas Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adamas Pharmaceuticals price performance over time

Historical closes compared with the close of $N/A from 2021-12-23

1 week (2022-09-17) N/A
1 month (2022-08-24) N/A
3 months (2022-06-24) N/A
6 months (2022-03-24) N/A
1 year (2021-09-27) -100.00%
2 years (2020-09-28) -100.00%
3 years (2019-09-27) -100.00%
5 years (2017-09-27) -100.00%

Adamas Pharmaceuticals financials

Revenue TTM $88.2 million
Gross profit TTM $72.4 million
Return on assets TTM -15.4%
Return on equity TTM 0%
Profit margin -71.11%
Book value $0.13
Market capitalisation $376.4 million

TTM: trailing 12 months

Adamas Pharmaceuticals share dividends

We're not expecting Adamas Pharmaceuticals to pay a dividend over the next 12 months.

Adamas Pharmaceuticals share price volatility

Over the last 12 months, Adamas Pharmaceuticals's shares have ranged in value from as little as $4.48 up to $8.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adamas Pharmaceuticals's is 2.8156. This would suggest that Adamas Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Adamas Pharmaceuticals overview

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Adamas Pharmaceuticals is owned by insiders or institutions?
Currently 0.714% of Adamas Pharmaceuticals shares are held by insiders and 79.346% by institutions.
How many people work for Adamas Pharmaceuticals?
Latest data suggests 138 work at Adamas Pharmaceuticals.
When does the fiscal year end for Adamas Pharmaceuticals?
Adamas Pharmaceuticals's fiscal year ends in December.
Where is Adamas Pharmaceuticals based?
Adamas Pharmaceuticals's address is: 1900 Powell Street, EmeryVille, CA, United States, 94608
What is Adamas Pharmaceuticals's ISIN number?
Adamas Pharmaceuticals's international securities identification number is: US00548A1060
What is Adamas Pharmaceuticals's CUSIP number?
Adamas Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00548A106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site